Western Health - Sunshine Hospital
Welcome,         Profile    Billing    Logout  
 1 Trial 
14 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
French, Craig
BoneZone, NCT04608630 / ACTRN12621000085875p: Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults

Recruiting
2
450
RoW
Denosumab 60 MG/ML, Prolia, Xgeva, Zoledronic Acid 5Mg/Bag 100Ml Inj, Zometa, Reclast, Aclasta, Sodium Chloride 0.9% or 5% Dextrose Intravenous, Saline, Placebo, Sodium Chloride 0.9% Injection
Australian and New Zealand Intensive Care Research Centre, Department of Health
Critical Illness, Osteoporosis
02/27
02/27
Egan, Elizabeth
NCT05427487: Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours

Recruiting
1
70
RoW
IVX037, Sintilimab
ImmVirx Pty Ltd, Innovent Biologics (Suzhou) Co. Ltd.
Colorectal Cancer, Gastric Cancer, Ovarian Cancer
09/26
11/26
Wong, Mark Y
PANOVA-3, NCT03377491: Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel

Completed
3
571
Europe, Canada, US, RoW
NovoTTF-200T, TTFields, Gemcitabine, nab paclitaxel
NovoCure Ltd.
Pancreas Adenocarcinoma
10/24
10/24
NCT05290597: A Phase 1, Open-label, Multicenter, Dose Escalation Study of IBI363 (PD1-IL2m) in Subjects with Advanced Solid Malignancies or Lymphomas

Recruiting
1
84
RoW
IBI363
Innovent Biologics (Suzhou) Co. Ltd., Fortvita Biologics (USA), Inc.
Solid Malignancies or Lymphomas
06/26
12/26
NCT05040932: Study of YH004 (4-1BB Agonist Antibody) in Advanced or Metastatic Malignancy

Completed
1
8
RoW
YH004
Eucure (Beijing) Biopharma Co., Ltd
Cancer
07/23
07/23
ACTM-838-01, NCT06336148: A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors

Recruiting
1
35
US, RoW
ACTM-838
Actym Therapeutics, Inc.
Solid Tumor
01/26
07/26
NCT05427487: Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours

Recruiting
1
70
RoW
IVX037, Sintilimab
ImmVirx Pty Ltd, Innovent Biologics (Suzhou) Co. Ltd.
Colorectal Cancer, Gastric Cancer, Ovarian Cancer
09/26
11/26
IGM-8444-001, NCT04553692: Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers

Active, not recruiting
1
272
Europe, US, RoW
Aplitabart (IGM-8444), FOLFIRI, Fluorouracil or 5-FU, Leucovorin, Irinotecan, Bevacizumab (and approved biosimilars), Avastin, Birinapant, Venetoclax, Venclexta, Gemcitabine, Gemzar, Docetaxel, Taxotere, Docefrez, Azacitidine, VIDAZA
IGM Biosciences, Inc.
Solid Tumor, Colorectal Cancer, Non Hodgkin Lymphoma, Sarcoma, Chondrosarcoma, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia
06/26
08/27
See, Emily
ACTRN12621001043820: Acute Renal effects of Angiotensin II Management In Shock (ARAMIS-2)

Recruiting
2
150
 
Austin Health, Austin Health Anaesthesia and Intensive Care Special Purpose Fund
Vasodilatory shock
 
 
BoneZone, NCT04608630 / ACTRN12621000085875p: Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults

Recruiting
2
450
RoW
Denosumab 60 MG/ML, Prolia, Xgeva, Zoledronic Acid 5Mg/Bag 100Ml Inj, Zometa, Reclast, Aclasta, Sodium Chloride 0.9% or 5% Dextrose Intravenous, Saline, Placebo, Sodium Chloride 0.9% Injection
Australian and New Zealand Intensive Care Research Centre, Department of Health
Critical Illness, Osteoporosis
02/27
02/27
ACTRN12621001566820p: NEt ultrafiltration Prescription and Targeting versus Usual NEt ultrafiltration during continuous renal replacement therapy

Not yet recruiting
N/A
1500
 
Australia and New Zealand Intensive Care Society Research Centre, Austin Health
Acute kidney injury; Continuous renal replacement therapy
 
 
ACTRN12621001566820: NEt ultrafiltration Prescription and Targeting versus Usual NEt ultrafiltration during continuous renal replacement therapy

Not yet recruiting
N/A
1500
 
Australia and New Zealand Intensive Care Society Research Centre, Austin Health
Acute kidney injury, Continuous renal replacement therapy
 
 
ACTRN12618002044202: Australasian Follow-up Tracking and Enhancing Recovery after Acute Kidney Injury (AFTER-AKI)

Recruiting
N/A
200
 
Austin Health, Austin Health
Acute kidney injury
 
 
ACTRN12616000905460: Mixed dilution haemodiafiltration versus post dilution haemodiafiltration in adults with end stage kidney disease: a prospective randomised crossover trial

Completed
N/A
25
 
Princess Alexandra Hospital, Princess Alexandra Hospital, Bundaberg Hospital
Haemodiafiltration, End stage kidney disease
 
 

Download Options